echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Officially included in the breakthrough therapy variety! Remegen Taitacept was again recognized for myasthenia gravis

    Officially included in the breakthrough therapy variety! Remegen Taitacept was again recognized for myasthenia gravis

    • Last Update: 2023-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 17, Rongchang Biopharmaceutical (Yantai) Co.
    , Ltd.
    (688331.
    SH/09995.
    HK) announced that tataceptept for injection (R&D code: RC18; Trade name: Taiai ®) was officially included in the breakthrough therapy variety by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration for the treatment of generalized myasthenia
    gravis.

    Breakthrough therapy drugs refer to innovative drugs or improved drugs
    that are used to prevent and treat diseases that are seriously life-threatening or seriously affect the quality of life, and there are no effective prevention and treatment methods, or have more significant or important treatment methods than existing treatments.
    For innovative drugs that include breakthrough therapy drugs, the Drug Review Center of the State Food and Drug Administration will prioritize the allocation of resources for communication, and the time to market of new drugs will be greatly shortened
    .

    The breakthrough treatment of tatacept by CDE is based on a domestic phase II.
    clinical study
    for the treatment of generalized myasthenia gravis.
    The study led by Professor Xu Xianhao of Beijing Hospital showed that tatacept could significantly improve the condition of patients with generalized myasthenia gravis, demonstrating good efficacy and safety
    .

    This is the second blockbuster recognition
    recently received by Tatacept in the field of myasthenia gravis.
    In October 2022, Remegen announced that Tatacept Myasthenia gravis has been granted orphan drug designation by the US Food and Drug Administration (FDA
    ).
    It is reported that the identified drugs can enjoy incentive policies
    such as fast track for marketing application, a 7-year market exclusivity period after listing, and tax incentives in the United States.

    About Tatacept

    Tatanercept is an antibody fusion protein drug molecule invented and designed by Professor Fang Jianmin, CEO and Chief Scientific Officer of Remegen Biologics, which inhibits the overexpression of two cytokines, BLyS and APRIL, and prevents the abnormal differentiation and maturation of B cells, thereby treating B-cell-mediated systemic lupus erythematosus and other autoimmune diseases
    .
    Due to the first treatment mechanism and new molecular design, the world's leading data have been obtained in the phase III clinical trial of systemic lupus erythematosus, with an effective rate of 82.
    6%, which is more than 30 percentage points
    higher than the existing international biological drugs.
    In March 2021, the indication of systemic lupus erythematosus (SLE) of tatacept was conditionally approved by the National Medical Products Administration (NMPA) of China, becoming the world's first dual-target biological new drug
    in the field of treatment of this disease.
    Phase III clinical studies of the drug for the treatment of rheumatoid arthritis, IgA nephritis, Sjogren's syndrome, neuromyelitis optica, myasthenia gravis, multiple sclerosis and other indications are advancing
    .

    About myasthenia gravis

    Myasthenia gravis (MG) is a rare, chronic autoimmune disease, caused by autoantibodies against acetylcholine receptors, muscle-specific kinases or other acetylcholine receptor-related proteins on the postsynaptic membrane, resulting in impaired neuromuscular junction transmission, which can affect eye movement, swallowing, speech, activity and respiratory function to varying degrees, about 85% of patients will have symptoms other than the eye muscle, develop into generalized myasthenia gravis (gMG), and even myasthenic crisis, has been included in China's " The first list of rare diseases"
    .
    At present, the main treatment methods of the disease include cholinesterase inhibitors, glucocorticoids and immunosuppressants, but there are still some patients who cannot fully and effectively control the disease due to drug efficacy, tolerability or contraindications, and there are a large number of unmet clinical needs
    .

    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.